Estrella Immunopharma, Inc.

Healthcare · Biotechnology · United States

Last price 0.7287 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 31.70M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to devel...